Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2022 3
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.
de Wijs LEM, Bosma AL, Erler NS, Hollestein LM, Gerbens LAA, Middelkamp-Hup MA, Kunkeler ACM, Nijsten TEC, Spuls PI, Hijnen DJ. de Wijs LEM, et al. Br J Dermatol. 2020 Feb;182(2):418-426. doi: 10.1111/bjd.18179. Epub 2019 Oct 16. Br J Dermatol. 2020. PMID: 31145810
Five patients discontinued dupilumab treatment due to side-effects or ineffectiveness. ...What does this study add? This study presents the first experience with dupilumab treatment in 95 patients with atopic derma
Five patients discontinued dupilumab treatment due to side-effects or ineffectiveness. ...What does this study a …
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS, Haeck I, Kamsteeg M, Van Lynden-van Nes AMT, Garritsen FM, Politiek K, Oldhoff M, De Graaf M, Schuttelaar MLA, De Bruin-Weller MS. Boesjes CM, et al. Acta Derm Venereol. 2022 Nov 24;102:adv00820. doi: 10.2340/actadv.v102.3978. Acta Derm Venereol. 2022. PMID: 36420885 Free article.
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of moderate-to-severe atopic dermatitis. However, daily practice data are limited. Therefore, this multicentr …
Clinical trials have shown that baricitinib, an oral selective Janus kinase 1/2 inhibitor, is effective for the treatment of m …
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis.
Achten RE, Van Luijk C, Van der Rijst L, Bakker D, Spekhorst L, Zuithoff N, Schuttelaar M, Romeijn G, Voorberg A, Kamsteeg M, Haeck I, De Graaf M, Thijs J, De Boer J, De Bruin-Weller M. Achten RE, et al. Acta Derm Venereol. 2022 Mar 11;102:adv00666. doi: 10.2340/actadv.v102.1128. Acta Derm Venereol. 2022. PMID: 35098318 Free PMC article.
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. ...In conclusion, a history of any e …
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderat …
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, Romeijn GLE, Loman L, Haeck I, Oosting AJ, de Boer-Brand A, Touwslager WRH, Flinterman A, van Lynden-van Nes AMT, Gostynski AH, de Bruin-Weller MS, Schuttelaar ML. Spekhorst LS, et al. JAMA Dermatol. 2022 Sep 1;158(9):1048-1056. doi: 10.1001/jamadermatol.2022.3014. JAMA Dermatol. 2022. PMID: 35947364
IMPORTANCE: Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. ...CONCLUSIONS AND RELEVANCE: This cohort study demonstrated a good overall 1-year, 2-year, and 3-year dupilumab drug survival. P
IMPORTANCE: Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. …